ST. JOSEPH, Mich., June 17 GeneGo, Inc., a leadingprovider of databases, software and services in systems biology, announcedtoday that they were awarded a Phase I SBIR from National Cancer Institute(NCI) for the development of a platform for functional data analysis incancer. GeneGo will collaborate with investigators at Dana-Farber CancerInstitute, Boston on the project. The system, MetaMiner (Oncology) willcombine pathway and network analysis tools, act as a OMICs data repository andhave advanced statistical tools based on functional descriptors.
"MetaMiner (Oncology) is a new generation pathway analysis tool,specifically tailored for biologists, clinicians and chemists working indifferent cancer areas," said Yuri Nikolsky, CEO of GeneGo and the grant's PI."Neoplasms are tremendously complex diseases, with many hundreds of perturbedpathways, both in terms of gain and loss of functions. We need to understandin a database structure the causal relationships between the involved pathwaysand the dynamics of pathway activation during tumorigenesis. These are twomain goals of the MetaMiner project."
"There are many 'generic' pathway tools on the market, helpful to someextent in cancer data analysis. However, none of them is centered aroundcancer biology, which is essential," said Kornelia Polyak, an AssociateProfessor at Dana-Farber Cancer Institute and a consultant on the grant."Another focus will be on the development of pathway-based tools forintegration of different types of OMICs data -- somatic mutations, high copynumber genes, epigenetics, gene expression, proteomics and metabolomics."
GeneGo develops systems biology technology for life science research. Theoriginal computational MetaDiscovery(TM) platform allows an integration andexpert analysis of different kinds of experimental data (mRNA expression,proteomics, metabolomics, microRNA assays and other phenotypic data) andrelevant bioactive chemistry (metabolites, drugs, other xenobiotics) withinthe framework of curated biological pathways and networks. GeneGo's flagshipproduct, MetaCore 4.7(TM), assists pharmaceutical scientists in the areas oftarget selection and validation, identification of biomarkers for diseasestates and toxicology. The second product, MetaDrug 4.7(TM) is designed forprediction of human metabolism, toxicity and biological effects for novelsmall molecules compounds. MetaBase(TM) represents the knowledge base forMetaCore. For more information, please visit the company's web site athttp://www.genego.com
MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM),MetaTox(TM), MetaMiner(TM) and 1-2-3 Workflow(TM) are trademarks of GeneGo,Inc.
SOURCE GeneGo, Inc.